Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder cancer is the 9th most common malignancy in the world, with urothelial carcinoma accounting for 90% of all histological subtypes. The majority of newly diagnosed cases are ’Non-muscle invasive’. The current standard of care for patients with low to high grade NMIBC relies on a combination of transurethral resection of bladder tumor (TURB-T) and intravesical instillation of Bacillus Calmette-Guérin (BCG). A significant portion of patients experience recurrence and are often faced with cystectomy (removal of the bladder) as their last treatment option. There is currently a significant unmet need to offer new options for these patients to remove recurrent tumors effectively, while preserving their bladder and their quality of life. ImPACT is currently being evaluated in preclinical studies for this indication.

©2020 by Steba Biotech. Proudly created with Wix.com

Steba biotech ©